ArticleInternational journal of cancer2020
Identifying predictors of HPV-related head and neck squamous cell carcinoma progression and survival through patient-derived models.
Article in International journal of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 54 citations in OpenAlex.
- Therapeutic resistance in HPV-positive oropharyngeal squamous cell carcinoma: molecular mechanisms, clinical challenges, and precision strategies.Frontiers in genetics · 2026Review
- Advances in oral disease models: a mini-review of developments from 2015 to 2025.Frontiers in dental medicine · 2026Review
- Article
- Squamous cell cancers of the aero-upper digestive tract: A unified perspective on biology, genetics, and therapy.Cancer cell · 2025Review
- Mapping herpesvirus-driven impacts on the cellular milieu and transcriptional profile of Kaposi sarcoma in patient-derived mouse models.bioRxiv : the preprint server for biology · 2024Article
- Fibroblasts Regulate the Transformation Potential of Human Papillomavirus-positive Keratinocytes.bioRxiv : the preprint server for biology · 2024Article
- The potential of hydrogel-free tumoroids in head and neck squamous cell carcinoma.Cancer medicine · 2024Review
- Clinical relevance and therapeutic predictive ability of hypoxia biomarkers in head and neck cancer tumour models.Molecular oncology · 2024Article
- Article
- In Vitro Models of Head and Neck Cancer: From Primitive to Most Advanced.Journal of personalized medicine · 2023Review
- To Tip or Not to Tip: A New Combination for Precision Medicine in Head and Neck Cancer.Cancer research · 2023Article
- HPV-positive murine oral squamous cell carcinoma: development and characterization of a new mouse tumor model for immunological studies.Journal of translational medicine · 2023Article
- A 3D Perfusable Platform for In Vitro Culture of Patient Derived Xenografts.Advanced healthcare materials · 2023Article
- The organoid as reliable cancer modeling in personalized medicine, does applicable in precision medicine of head and neck squamous cell carcinoma?The pharmacogenomics journal · 2023Review
- Therapeutic implications of transcriptomics in head and neck cancer patient-derived xenografts.PloS one · 2023Article
- The applications and techniques of organoids in head and neck cancer therapy.Frontiers in oncology · 2023Review
- Systematic Analysis of IL-1 Cytokine Signaling Suppression by HPV16 Oncoproteins.Journal of virology · 2022Article
- HPV E6 regulates therapy responses in oropharyngeal cancer by repressing the PGC-1α/ERRα axis.JCI insight · 2022Article
- Tumor Cell Extrinsic Synaptogyrin 3 Expression as a Diagnostic and Prognostic Biomarker in Head and Neck Cancer.Cancer research communications · 2022Article
- Oropharyngeal cancer outcomes correlate with p16 status, multinucleation and immune infiltration.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 7 institutions in 1 country.
Funding
Abstract
Therapeutic innovation for human papilloma virus-related (HPV+) head and neck squamous cell carcinomas (HNSCCs) is impaired by inadequate preclinical models and the absence of accurate biomarkers. Our study establishes the first well-characterized panel of patient-derived xenografts (PDXs) and organoids from HPV+ HNSCCs while determining fidelity of the models to the distinguishing genetic features of this cancer type. Despite low engraftment rates, whole exome sequencing showed that PDXs retain multiple distinguishing features of HPV+ HNSCC lost in existing cell lines, including PIK3CA mutations, TRAF3 deletion and the absence of EGFR amplifications. Engrafted HPV+ tumors frequently contained NOTCH1 mutations, thus providing new models for a negatively prognostic alteration in this disease. Genotype-phenotype associations in the models were then tested for prediction of tumor progression and survival in published clinical cohorts. Observation of high tumor mutational burdens (TMBs) in the faster-growing models facilitated identification of a novel association between TMB and local progression in both HPV+ and HPV- patients that was prognostic in HPV- cases. In addition, reduced E7 and p16
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.